Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - February 12, 2024) - BioHarvest Sciences Inc., (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) ("BioHarvest" or "the Company"), a pioneer in Botanical Synthesis technology that grows Phyto-active compositions without growing the plant, announces its upcoming participation and sponsorship of the 2024 BIO CEO & Investor Conference, which will take place in New York City from February 26-27, 2024.
Ilan Sobel, Chief Executive Officer of BioHarvest, is scheduled to host one-on-one meetings with qualified institutional investors throughout the conference. He will be joined by the Company's Chairman, Zaki Rakib, and Chief Medical Officer, Dr. Brian Cornblatt. In addition, Mr. Sobel is scheduled to host a presentation to attendees as follows:
2024 Bio CEO & Investor Conference
Date: Monday, February 26, 2024
Time: 10:00 a.m. Eastern standard time
Location: The New York Marriott Marquis | 1535 Broadway, New York, NY
"The BIO CEO & Investor Conference is one of the largest and most prestigious global events for biotechnology investors, representing an ideal forum for us to showcase our disruptive botanical synthesis platform and upcoming growth catalysts for 2024," said Ilan Sobel, CEO of BioHarvest. "The strategic steps we have taken over the past twelve months have put BioHarvest in a stronger position than ever to accelerate our rapid growth trajectory and drive sustainable shareholder value over the long term. That said, I look forward to our upcoming presentation, which will be showcased to some of the industry's most sophisticated investors and influencers."
The Company invites interested BIO CEO & Investor Conference attendees to request a meeting via the 1x1 system. CEO Ilan Sobel and Chairman Zaki Rakib will host additional investor meetings outside of the conference. To learn more or to request a meeting, please contact the Company's investor relations team at info@bioharvest.com.
About BIO CEO & Investor Conference
The BIO CEO & Investor Conference provides timely and relevant content on the issues driving the business of biotech, along with an invaluable platform for networking and partnering. The conference brings together biotech executives with the investment community to discover the latest innovations in biotech during Company Presentations and to hear from thought-leaders during sessions on therapeutic advancements, market outlook, and policy priorities. To learn more, visit the conference website at https://bcic.bio.org/.
For further information, please contact:
BioHarvest Sciences Investor Relations
+1 (778) 686-3855
info@bioharvest.com
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow the active ingredients in plants, without the need to grow the underlying plant. BioHarvest is currently focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions, within two major business verticals - nutraceutical health and wellness products such as dietary supplements, and development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications. To learn more, please visit www.bioharvest.com.
Forward-Looking Statements
Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.
All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.
Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/197589
